

K060372

5

510(k) Summary

5 510(k) Summary

AUG 16 2006

This 510(k) summary of safety and effectiveness information is being submitted in accordance with the requirements of 21 CFR 807.92(a).

5.1 SUBMITTER'S NAME, ADDRESS, TELEPHONE NUMBER, CONTACT PERSON, AND DATE SUMMARY PREPARED

a. Applicant: IntraLase Corp.
9701 Jeronimo Road
Irvine, CA 92618
Tel: (949) 859-5230
Fax: (949) 330-0512

b. Contact Person: Charline Gauthier, OD, PhD
Executive Vice President & Chief Operating Officer
IntraLase Corp.
Tel: (949) 859-5230
Fax: (949) 330-0512

c. Date Summary Prepared February 7, 2006

5.2 NAME OF DEVICE, INCLUDING THE TRADE NAME AND CLASSIFICATION NAME:

a. Trade/Proprietary Name: IntraLase FS Laser

b. Common/Usual Name: Laser

c. Classification Name: Keratome

d. Classification Code(s): 79 GEX
86 HNO

5.3 IDENTIFICATION OF THE PREDICATE DEVICE OR LEGALLY MARKETED DEVICE OR DEVICES TO WHICH SUBSTANTIAL EQUIVALENCE IS BEING CLAIMED:

510(k) #	Trade Name	Manufacturer
K993153	IntraLase 600C Laser Keratome	IntraLase Corp.
K001211	IntraLase 600C Laser Keratome	IntraLase Corp.
K002890	IntraLase 600C Laser Keratome	IntraLase Corp.
K013941	Pulsion FS Laser Keratome	IntraLase Corp.
K031960	IntraLase FS Laser	IntraLase Corp.
K041893	IntraLase FS Laser	IntraLase Corp.

5.4 A DESCRIPTION OF THE DEVICE THAT IS THE SUBJECT OF THE 510(K), INCLUDING EXPLANATION OF HOW THE DEVICE FUNCTIONS, BASIC SCIENTIFIC CONCEPTS, SIGNIFICANT PHYSICAL AND PERFORMANCE CHARACTERISTICS (DESIGN, MATERIAL, PHYSICAL PROPERTIES):

The IntraLase FS Laser is a precision ophthalmic surgical laser designed for use in performing lamellar corneal resections and incisions.

The cutting action of the IntraLase FS Laser is achieved through precise individual micro-photodisruptions of tissue, created by tightly focused ultrashort pulses which are delivered through a disposable applanation lens while fixating the eye under very low vacuum.

5.5 STATEMENT OF INTENDED USE:

The IntraLase® FS Laser is an ophthalmic surgical laser with the following indications for use:

- In patients undergoing surgery or other treatment requiring initial lamellar resection of the cornea;
- In patients undergoing surgery or other treatment requiring initial lamellar resection of the cornea to create tunnels for placement of corneal ring segments;
- In lamellar keratoplasty and corneal harvesting;
- In the creation of a corneal flap in patients undergoing LASIK surgery or other treatment requiring initial lamellar resection of the cornea;
- In the creation of lamellar cut/resection of the cornea for lamellar keratoplasty and in the creation of penetrating cut/incision for penetrating keratoplasty.

5.6 STATEMENT OF HOW THE TECHNOLOGICAL CHARACTERISTICS OF THE DEVICE COMPARE TO THOSE OF THE PREDICATE OF LEGALLY MARKETED DEVICE.

The technological characteristics of the IntraLase FS Laser have already been cleared under K041893, K031960, K013941, K002890, K001211 and K993153 for lamellar corneal resections and incisions. The changes made to the labeling do not alter the performance or indication of this device.

5.7 BRIEF SUMMARY OF NONCLINICAL TESTS AND RESULTS:

The IntraLase FS Laser has undergone testing and is in compliance with applicable safety standards. The IntraLase FS and the accessory IntraLase Patient Interface were found to perform equivalently to the predicate Laser for the creation of corneal resections with respect to incremental changes. Thus, the IntraLase FS Laser and the predicate device have similar safety, effectiveness and performance profiles.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
10903 New Hampshire Avenue
Document Control Room -WO66-G609
Silver Spring, MD 20993-0002

JAN 25 2011

Intralase Corporation
c/o Charlene Gauthier, OD, Ph.D.
Executive Vice President and Chief Operating Officer
9701 San Jeronimo Rd.
Irvine, CA 92618

Re: K060372

Trade/Device Name: INTRALASE® FS Laser Model 1, Model 2 and the INTRALASE®
FS30 Laser Model 3

Regulation Number: 21 CFR 878.4810

Regulation Name: Laser

Regulatory Class: II

Product Code: GEX, HNO

Dated: April 4, 2006

Received: April 7, 2006

Dear Dr. Gauthier:

This letter corrects our substantially equivalent letter of August 16, 2006.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set


forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

<http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,



Malvina B. Eydelman, M.D.

Director

Division of Ophthalmic, Neurological,

and Ear, Nose and Throat Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Indications for Use

510(k) Number (if known): K060372

Device Name(s): IntraLase FS Laser

Indications for Use:

The IntraLase® FS Laser is an ophthalmic surgical laser with the following indications for use:

- In patients undergoing surgery or other treatment requiring initial lamellar resection of the cornea;
- In patients undergoing surgery or other treatment requiring initial lamellar resection of the cornea to create tunnels for placement of corneal ring segments;
- In lamellar keratoplasty and corneal harvesting;
- In the creation of a corneal flap in patients undergoing LASIK surgery or other treatment requiring initial lamellar resection of the cornea;
- In the creation of a lamellar cut/resection of the cornea for lamellar keratoplasty and in the creation of a penetrating cut/incision for penetrating keratoplasty.

Prescription Use X
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use _____
(21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF
NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)


(Division Sign-Off)
Division of Ophthalmic, Neurological and Ear,
Nose and Throat Devices

Page 1 of 1

510(k) Number K060372